Themis Medicare Ltd

NSE
THEMISMED •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Themis Medicare Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
New 52W High in past week
54.2
TTM PE Ratio
Above industry Median
48.5
Price to Book Ratio
Below industry Median
6.5
Dividend yield 1yr %
Low in industry
0.2
TTM PEG Ratio
PEG TTM is negative
-2.2
RSI
RSI is mid-range
59.1
MFI
MFI is mid-range
68.9

Themis Medicare Ltd Key Financials

*All values are in ₹ Cr.

Themis Medicare Ltd shareholding Pattern

Promoter
67.2%
Public
32.8%

Themis Medicare Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
15
Bearish Moving Averages
1
5Day EMA
237.60
10Day EMA
234.00
12Day EMA
232.90
20Day EMA
229.30
26Day EMA
226.70
50Day EMA
216.20
100Day EMA
199.40
200Day EMA
178.20
Delivery & Volume
Resistance & Support
237.25
Pivot
Resistance
First Resistance
243.45
Second Resistance
248.20
Third Resistance
254.40
Support
First Support
232.50
Second support
226.30
Third Support
221.55
Relative Strength Index
59.13
Money Flow Index
68.89
MACD
6.23
MACD Signal
5.27
Average True Range
12.91
Average Directional Index
27.55
Rate of Change (21)
8.60
Rate of Change (125)
46.63

Themis Medicare Ltd Company background

Founded in: 1969
Incorporated in 1969, Themis Medicare Ltd., formerly known as Themis Chemicals (TCL) was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April 93. The Group is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity.In Mar.95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansioncummodernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment longterm working capital.Total cost of the project was estimated at Rs 17.64 cr. TCL manufactures and sells synthetic bulk drugs and formulations. It operates in the therapeutic segments of antituberculosis, cerebroactivators, bronchodilators, antiasthmatic, anaesthetic and other segments.Antituberculosis bulk drugs and formulations account for 60% of its turnover and the company is rated fourth in terms of turnover in this segment. TCL has also started manufacturing and exporting fumagillin, an antibacterial drug, for veterinary use for which it has a confirmed buyback arrangement with Chinoin, Hungary.The company with the help of M/s Pharmograd,Moscow a manufacturing unit, is planning to market its AntiT.B.formulation products through the collborators throughout the Russian Federation for trade,tenders and govt.supplies.The Company introduced products like Cardiac and Muscular Relaxant during the year 200102. A wholly owned subsidiary of the Company, Themis Medicare Singapore Pte. Ltd., formed on 22nd May, 2002 in Singapore became operational during the year 200203. M/s. Artemis Biotech Ltd., a Group Company was merged with Themis Medicare Ltd. (the Parent Company) with effect from 1st April 2003. The Joint Venture Company, Richter Themis Medicare (India) Pvt. Ltd. started manufacturing activities at its EOU unit at Vapi effective from March, 2006. The Company started operations of its new Injection Plant at Haridwar for tablets and gel formulation production in 200607. Themiseal, the Companys unique haemostatic and antimicrobial product was launched in the UK, Greece, Cyprus, Jordan, Romania and Indonesia.During the year 201011, a Private Ltd Subsidiary Company in the name and style of Themis Lifestyle Pvt. Ltd was incorporated on 3rd November, 2010 and another Public Ltd Subsidiary Company in the name and style of Artemis Biotech Ltd. was incorporated on 14th January, 2011.During FY 201617, HIDPUL KFT (Hungary), a Wholly Owned Subsidiary of the Company, ceased to be a subsidiary of the Company. Carpo Medical Limited was incorporated as a Joint Venture Company in the United Kingdom in 201617.
Read More

Themis Medicare Ltd FAQs

Themis Medicare Ltd shares are currently priced at 238.7 on NSE and 239.1 on BSE as of 2/22/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Themis Medicare Ltd [THEMISMED] share was 86.99. The Themis Medicare Ltd [THEMISMED] share hit a 1-year low of Rs. 109.64 and a 1-year high of Rs. 254.

The market cap of Themis Medicare Ltd is Rs. 2196.7 Cr. as of 2/22/2024 12:00:00 AM.

The PE ratios of Themis Medicare Ltd is 79.44 as of 2/22/2024 12:00:00 AM.

The PB ratios of Themis Medicare Ltd is 8.36 as of 2/22/2024 12:00:00 AM

You can easily buy Themis Medicare Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage